Hubei JXBio Pharmaceutical Co., Ltd.: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Hubei JXBio Pharmaceutical Co., Ltd.?
Yes. FDA’s import refusal records list 1 refused shipment line declared as made by Hubei JXBio Pharmaceutical Co., Ltd. (China) whose FDA product code names tirzepatide, on Aug 5, 2024. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Xianning
- FEI numbers on the lines
- 3016784508
- Refused lines
- 1
- Lines with an Import Alert 66-80 API or powder code
- 1
- Drugs named in the product codes
- Tirzepatide
- Refusal dates
- Aug 5, 2024
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Hubei JXBio Pharmaceutical Co., Ltd. is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Aug 5, 2024 | China | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | XXX-0614347-6/1/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1 |
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 4 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Hubei JXBio Pharmaceutical Co., Ltd” and “Hubei JXBio Pharmaceutical Co.,Ltd”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (3); BULK INGREDIENT (1).
| 76617-002 | Hubei JXBio Pharmaceutical Co., Ltd | Not given | liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Mar 14, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
| 76617-001 | Hubei JXBio Pharmaceutical Co.,Ltd | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Nov 17, 2022 | None given | Dec 31, 2026 | Unfinished drugs |
| 76617-003 | Hubei JXBio Pharmaceutical Co.,Ltd | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jan 9, 2025 | None given | Dec 31, 2027 | Unfinished drugs |
| 76617-020 | Hubei JXBio Pharmaceutical Co.,Ltd | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | Dec 5, 2022 | None given | Dec 31, 2026 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.
1 line from FDA files read Nov 15, 2026.